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Abstract 
Cardiovascular fitness is reduced in people with schizophrenia and is related to an increased 
morbidity and mortality. There is mounting interest in the accurate measurement of 
cardiovascular fitness in schizophrenia, yet existing measures used in the general population 
have not been tested on validity and reliability in this high-risk group. Therefore, we 
examined the reproducibility and feasibility of the Astrand-Rhyming sub-maximal exercise 
test in patients with schizophrenia or schizoaffective disorder. Secondary aims were to assess 
minimal detectable changes, practice effects and the presence of clinical symptoms that are 
associated with cardio-respiratory fitness (expressed as estimated oxygen uptake). From 47 
patients with schizophrenia or schizoaffective disorder two trials of the Astrand-Rhyming test, 
administered within three days, were analysed. The intraclass correlation coefficient for the 
estimated oxygen uptake between the two tests was 0.92 (95% confidence interval: 0.85 to 
0.95). The minimal detectable change was 6.5mlO2/min/kg. No practice effect could be 
detected. A backward regression analysis demonstrated that illness duration, negative 
symptoms and level of physical activity explained 63.0% of the variance in estimated oxygen 
uptake. The current study demonstrates that the Astrand-Rhyming test can be recommended 
for evaluating the aerobic fitness in patients with schizophrenia or schizoaffective disorder. 
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1. Introduction 
In persons with schizophrenia or schizoaffective disorder, an impaired aerobic fitness is a 
major modifiable risk factor for cardiovascular disease and overall morbidity and mortality 
(Strassnig et al., 2011; Scheewe et al., 2012; Vancampfort et al., 2013a). For this reason, an 
impaired aerobic fitness is an important indicator for physical activity interventions within the 
multidisciplinary treatment of patients with schizophrenia (Stubbs et al., 2014; Uwakwe et al., 
2014; Vancampfort et al., 2009, 2010). Given that physical activity might be beneficial in the 
prevention of cardiovascular diseases, support for aerobic exercise programmes in the 
multidisciplinary treatment of schizophrenia and schizoaffective disorder is growing 
(Scheewe et al., 2012, 2013; Strassnig et al., 2012; Vancampfort et al., 2012a, b).  
Until recently, the promotion of aerobic fitness in patients with schizophrenia or 
schizoaffective disorder has received limited attention, in part due to lack of appropriate 
measures (De Hert et al., 2011; Vancampfort et al., 2011a). Laboratory-based incremental 
exercise testing protocols, that use breath-by-breath gas analysis and measure the maximum 
level of oxygen consumption (VO2max) are considered the ‘gold standard’ measurement of 
aerobic fitness  (Vanhees et al., 2005). However, these test protocols are time-consuming, 
costly and need highly sophisticated equipment (Vanhees et al., 2005), which is often not 
available or practical in mental health care settings. Moreover, the maximal nature of the test 
may be influenced by the motivation of participants (Strassnig et al., 2011; Vancampfort et 
al., 2013b). Submaximal exercise tests that use measures of heart rate (HR) to estimate 
V02max are considered to be a reliable and valid measure of aerobic fitness (Lambrick, 
Faulkner, Rowlands, Eston, 2009). Importantly, for high-risk populations, submaximal tests 
are safer, better tolerated and consequently ideal for monitoring levels of aerobic fitness 
(Vanhees et al., 2005). A further benefit of submaximal testing is that it can allow greater 
numbers of patients to be longitudinally monitored at minimum costs. To date, there is no 
sub-maximal test which has been validated to assess the aerobic fitness of patients with 
schizophrenia.  
One test which could be considered is the Astrand-Rhyming test (Astrand, 1960). The 
test utilizes a six minute, single stage, submaximal cycle ergometer protocol and is considered 
suitable for testing the general population (American College of Sports Medicine, 2013). 
Using this test, research (Nilsson et al., 2012; Ozbulut et al., 2013) has identified that patients 
with schizophrenia have a significantly lower aerobic fitness compared with age- and gender 
matched healthy controls. In order to validate these findings, help capture and reduce the 
burden of cardiovascular disease in individuals with schizophrenia, and further provide 
clinical practice a validated submaximal test of aerobic fitness, it is important that the 
psychometric properties of the Astrand-Rhyming test are considered. Therefore, the aims of 
this study follow a series of iterative steps: (a) to investigate the test-retest reliability of the 
Astrand-Rhyming test in patients with schizophrenia or schizoaffective disorder, (b) to 
determine limits for the smallest difference in VO2max that indicated a clinically meaningful 
change, (c) to explore whether there was a practice effect with repeated testing, (d) to assess 
clinical and demographic characteristics that might interfere with the test performance, and (e) 
to describe the feasibility of the test in patients with schizophrenia or schizoaffective disorder. 
 
2. Methods 
2.1. Participants 
Over a 5-month period, inpatients with a DSM-V diagnosis of schizophrenia or 
schizoaffective disorder (American Psychiatric Association, 2013) admitted to the UPC KU 
Leuven in Belgium were invited to participate. Patients were excluded if they had a current 
co-morbid DSM-V diagnosis of substance abuse (American Psychiatric Association, 2013). 
The somatic exclusion criteria included evidence of significant cardiovascular, neuromuscular 
and endocrine disorders which, according to the American College of Sports Medicine 
(2013), might prevent safe participation in the study. All participants received a physical 
examination and baseline electrocardiogram before testing. Participants taking beta-blocking 
agents were excluded due to the potential influence on heart rate (HR) response. The study 
procedure was approved by the Scientific and Ethical Committee of the UPC KU Leuven, 
campus Kortenberg, Belgium in accordance with the principles of the Declaration of Helsinki. 
All participants gave their informed written consent. There was no compensation for 
participation in the study. 
 
 
2.2. Sample size analysis 
An a-priori sample size calculation was conducted. With a minimal acceptable intraclass 
correlation coefficient (ICC) of 0.80 and the hypothesis based on previous research 
(Vancampfort et al., 2011b; Vancampfort et al., 2012c) that present findings would be 
consistent with a minimum ICC of 0.90, a minimum sample size of 46 patients was required 
to attain a level of significance (α) of 0.05 and power of 0.8 (β = 0.2) (Donner and Eliasziw, 
1987; Walter et al., 1998). Considering previous reliability studies in patients with 
schizophrenia (Vancampfort et al., 2011b; Vancampfort et al., 2012c), it was anticipated that 
approximately 15% of patients would be excluded a-priori, approximately 15% would decline 
participation for motivational reasons and approximately 15% would dropout from the testing 
for motivational or other reasons. Therefore, a sample size around 75-80 participants was pre-
specified to allow for these potential factors.   
 
2.3. Study design 
A test-retest design was used to test the reproducibility of the Astrand-Rhyming test (Astrand, 
1960). Two tests were undertaken with the second test being repeated within three days by the 
same trained mental health physical therapist. 
 
2.4. Astrand-Rhyming test 
The Astrand-Rhyming protocol (Astrand, 1960) is a single-stage cycle ergometer test 
designed to elicit a steady-state heart rate over a 6-min period. The initial workload is selected 
from the Astrand test loading wattage table, pedaling speed remains constant (60 revolutions 
per min) and HR is recorded at every minute interval. The workload is set during the first 2 
min and maintained throughout the test. In the case that HR fails to achieve the target zone, 
the load is adjusted accordingly. HR and loading wattage are noted at the end of each minute, 
with a target goal of obtaining two consecutive HR values over 120 beats per minute (bpm), 
within 5 bpm of each other, during the fifth and sixth minute of work. The protocol was to be 
interrupted if threatening symptoms appeared or when the HR reached 85% of age-predicted 
(220-age) maximum HR. Oxygen uptake (VO2) was estimated using the Astrand-Rhyming 
gender-sensitive nomogram (Astrand, 1960; American College of Sports Medicine, 2013). 
Results were then normalised to age. 
 
2.5. Testing procedures 
The testing procedures were performed according to the American College of Sports 
Medicine guidelines (2013) in an indoor gym room with a minimum of external stimuli (e.g. 
no other participants present during the test). The therapist used a standardised instruction and 
language for each test and did not provide any verbal encouragement Patients were requested 
to refrain from eating, drinking coffee or smoking during a two-hour period prior to the tests. 
At testing days medication was taken at the same hour of the day. Patients performed the 
retest at the same hour in standardised conditions. Blood pressure (BP) was before, during and 
after the test recorded with an Omron M6 (HEM-7001-E). HR was monitored continuously 
during testing by Polar HR monitors (Polar Heart Rate Monitor, Polar Oy, Kempele, Finland). 
 
2.6. Psychosis evaluation tool for common use by caregivers (PECC) 
The PECC was used to assess schizophrenia symptoms (De Hert et al., 1998). The assessment 
was made prior to the first Astrand test by an independent mental health nurse. The assessor 
was blinded to all the other assessments and was provided with training on how to administer 
the PECC. The semi-structured PECC-interview evaluates 20 symptom items on a 7-point 
scale. Symptoms are grouped in 5 factors: positive, negative, depressive, cognitive and 
excitatory symptoms. The scores for each factor range from 4 to 28. Also extrapyramidal 
side-effects of antipsychotic medication (EPS) were evaluated with the PECC-instrument. 
Scores range from 4 to 16. Higher scores indicate more severe side-effects. Validation results 
demonstrate that the PECC can be used for the evaluation of these symptoms and side-effects 
in schizophrenia or schizoaffective disorder (De Hert et al., 2002). 
 
2.7. Physical activity participation 
The International Physical Activity Questionnaire (IPAQ) (Craig et al., 2003) was used to 
assess the level of physical activity. The IPAQ asks participants to recall activities for each of 
the last seven preceding days in morning, afternoon, and evening time periods. On the basis of 
what activities participants self-reported, the interviewer (blinded physical therapist) also 
clarified the perceived intensity of that specific activity. A continuous indicator was 
calculated as a sum of weekly metabolic equivalent (MET)-minutes per week of physical 
activity. The MET energy expenditure was estimated by weighting the reported minutes per 
week by a MET energy expenditure estimate for each type of activity (low, moderate and 
vigorous intensity physical activity). The weighted MET-minutes per week were calculated as 
duration x frequency per week x MET-intensity, which were then summed to produce a 
weighted estimate of the total physical activity from all reported activities per week as per the 
IPAQ scoring protocol. Previous research indicated that the IPAQ can be considered as a 
reliable surveillance tool to assess levels of physical activity in patients with schizophrenia 
(Faulkner et al., 2006). 
 
2.8. Medication use 
Antipsychotic medication was  recorded  for each patient and converted into a daily equivalent 
dosage of chlorpromazine according to consensus by Gardner et al. (2010). Data on the use of 
medication was obtained from patients’ medical records.  
 2.9. Other clinical variables 
Body weight was measured by the (blinded) research nurse in light clothing to the nearest 0.1 
kg using a SECA beam balance scale, and height to the nearest 0.1 cm using a wall-mounted 
stadiometer. Illness duration and data on physical co-morbidity were obtained from patients’ 
medical records. Metabolic syndrome was assessed using the International Diabetes 
Federation criteria (Alberti et al., 2006). 
 
2.10. Statistical analyses 
Descriptive statistics are presented as mean ± standard deviation (SD). In order to assess the 
reliability between the two Astrand-Rhyming tests, the intraclass correlation coefficient (ICC) 
and its associated 95% confidence interval (CI) of the oxygen uptake estimates between the 
two Astrand-Rhyming tests were calculated using a one-way random single measures 
intraclass correlation analysis.  
The minimal detectable change (MDC) for was calculated by multiplying the standard 
error of measurement (SEM) by 1.96 to correspond to the 95% CI and the square root of two 
to adjust for sampling from two different measurements. The SEM was estimated as the 
pooled standard deviation (SD) of pre-test and post-test assessments multiplied by the square 
root of (1-ICC) (de Vet et al., 2006). The SEM quantifies the within-subject variability and 
takes the amount of measurement errors into consideration. MDC95 means one can be 95% 
confident that a change score equal or exceeding this threshold is true and reliable and not just 
a measurement error (Portney and Watkins, 2009).  
To assess whether there was a practice effect with repeated testing, the four following 
methods were used. First, the ICC was interpreted. An ICC of less than 0.75 for the two 
successive tests was indicative of a practice effect (Portney and Watkins, 2009). The second 
method was a Pearson correlation (r) of less than 0.75 between successive trials. When the r-
value equals 1, there is perfect agreement between both trials, and the Pearson correlation and 
the ICC concur in value. The third method was a statistically significant (P<0.05) 
improvement in the mean Astrand-Rhyming test scores between two trials, evaluated with a 
paired T-test and expressed with the 95% CI. The fourth method was the Bland-Altman 
method illustrating the means and the differences in oxygen uptake estimates of the Astrand-
Rhyming tests for each subject (Bland and Altman, 2007). A P-value for the Spearman rank 
correlation coefficient between the means and the differences in oxygen uptake estimates of 
less than 0.05 indicates that the magnitude of the difference in oxygen uptake at baseline 
varies by the level of aerobic fitness. Because previous studies have not operationally defined 
practice effects and no single method of evaluation has been identified as superior to the 
others, the present study considers in parallel with a previous study in patients with 
schizophrenia (Vancampfort et al., 2011b) that a practice effect was to be present only if all 
four criteria have been fulfilled.  
Pearson correlations were used to compute associations between the oxygen uptake 
estimates and demographical data and other variables. To identify independent predictors of 
the estimated oxygen uptake oxygen uptake (VO2) obtained on the second trial, a backward 
regression analysis including all significant correlates was conducted. A priori, a level of 
significance was set at P<0.05.  
Statistical analysis was performed using the statistical package SPSS version 22.0 
(SPSS Inc., Chicago, IL). 
 
 
 
 
3. Results 
3.1. Participants 
Out of 77 patients with schizophrenia or schizoaffective disorder, 66 met the inclusion criteria 
of which 19 declined to participate (n=15) or dropped-out (n=4). Reasons for exclusion and 
drop-out are presented in Figure 1. The gender distribution of the final included sample was 
34 men (34.1±12.0 years; BMI=25.4±3.2) and 13 women (34.3±9.2 years; BMI=27.1±6.6). 
Age ranged from 20 to 62 years. Seventy-six percent of the patients (n=36) smoked. All 
individuals were Caucasians, and all except two were treated with antipsychotic drugs at the 
moment of the assessments. An overview of the medication intake is presented in Table 1. 
Mean daily equivalent dosage of chlorpromazine (n=45) was 678.5 ± 394.9 mg/day. 
Physical co-morbidity of the included patients is presented in Table 2. In summary, the most 
common co-morbid conditions were respiratory diseases, cardiovascular diseases, locomotor 
disorders, diabetes and the metabolic syndrome. 
 
3.2. Astrand-Rhyming test scores in schizophrenia or schizoaffective disorder 
The mean estimated VO2 on the first and second test were respectively 34.6±8.7mlO2/min/kg 
and 34.5±8.7 mlO2/min/kg. When looking at the mean oxygen consumption at steady state of 
both tests, it was noticed that there was no gender difference in VO2 (35.3±8.6mlO2/min/kg in 
men versus 32.1±9.0mlO2/min/kg in women, P=0.29). 
 
3.3. Reliability and minimal detectable changes of the Astrand-Rhyming test 
Analyses of reproducibility of the Astrand-Rhyming test showed that the ICC for the whole 
sample was 0.92 with a 95% CI of 0.85-0.95. The MDC95 in the present study was 
6.5mlO2/min/kg. 
 
3.4. Determination of a practice effect 
The correlation between Astrand-Rhyming test scores at trial one and two was 0.91 
(P<0.001). A r2 value of 0.835 indicated that the performance on trial one explained 83.5% of 
the variability in the trial two performance. The VO2 on the second trial was not significantly 
different to the VO2 obtained on the first trial (P=0.79). The Bland-Altman plot in figure 2 
showed no significant pattern between the mean VO2 scores and differences in VO2 scores at 
the individual level, and this was supported by a Spearman rank correlation coefficient of -
0.08 with a P-value of 0.59. The plot revealed one outlier: a male participant (23 years old, 
BMI=22.1) who had an estimated VO2 of 40ml O2/min/kg based on a workload of 125 Watt 
and a mean steady state HR of 139bpm (at min five and six) at the first trial showed a steady 
state HR of 157 bpm at a same workload on the second trial, which corresponds with a VO2 of 
32ml O2/min/kg. As expected, 95% of the differences were within 2 SDs of the mean.  
 
3.5. Variables associated with the Astrand-Rhyming test 
Table 3 shows that age (P=0.043), illness duration (P=0.003), BMI (P<0.001), negative 
(P=0.004), depressive (P=0.005), cognitive (P=0.001) symptoms and extrapyramidal side-
effects (P =0.006) were negatively associated with the estimated oxygen uptake. Higher levels 
of physical activity (P <0.001) was positively associated with oxygen uptake.  
All significant correlates were included in a backward regression analysis with the estimated 
oxygen uptake as the dependent variable. Within the fully adjusted model, the largest unique 
significant predictor of oxygen uptake was physical activity levels (β=0.48, p<0.001), 
followed by illness duration (β=-0.31, p<0.001) and negative symptoms (β=-0.22, p=0.034). 
The model explained 63.0% of the variance in estimated oxygen uptake. 
 
 
4. Discussion 
4.1. Reliability and minimal detectable changes 
This is the first study investigating the reliability of the Astrand-Rhyming sub-maximal 
exercise test in patients with schizophrenia or schizoaffective disorder. Our findings 
demonstrate that this sub-maximal aerobic test is both highly reproducible and reliable. With 
the mounting calls to reduce the increased mortality due to cardiovascular disease in people 
with schizophrenia, our results demonstrate promise and suggest that the Astrand-Rhyming 
test can be suitably used to monitor aerobic fitness in this population.  
Interpreting change scores and identifying clinically significant changes in performance 
have become an explicit focus of the rehabilitation profession in mental health care settings 
(Vancampfort et al., 2012d). Clinicians are encouraged to understand how changes in scores 
translate to clinical relevance. The present study calculated the MDC95, which provides 
meaningful criteria for assessing performance changes. A MDC95 of 6.5mlO2/min/kg implies 
that greater changes in oxygen uptake than these values are necessary on the Astrand-
Rhyming test in order to be 95% certain that the changes are not due to measurement error or 
patient variability. Previous research in patients with schizophrenia demonstrated that such 
changes in oxygen uptake are achievable after a 6-week, 3 times a week 30min cardiovascular 
exercise programme  (Strassnig et al., 2012). 
The treatment of schizophrenia should therefore target improvement of aerobic fitness. 
This study adds to current knowledge that the oxygen uptake as assessed with the Astrand-
Rhyming test could be a clinically relevant outcome measure. 
 
4.2. Practice effects 
Since the ICC and the correlation between both estimated VO2 scores were higher than 0.75, 
the P-value of the Spearman correlation between the means and differences in Astrand-
Rhyming test scores was higher than 0.05 and the VO2 at the second trial was not significantly 
different compared with the first, a practice effect can be excluded. The present study 
therefore indicates that a habituation test should not be recommended to offset any practice 
effects. 
 
4.3. Factors associated with the Astrand-Rhyming test performance 
The backward regression analysis demonstrated that longer illness duration and more severe 
negative symptoms might explain a lower aerobic fitness. Previous research on physical 
activity correlates in patients with schizophrenia and schizoaffective disorder showed that 
longer illness duration and more severe negative symptoms are associated with a sedentary 
lifestyle and lack of physical activity (Vancampfort et al., 2012e; Vancampfort et al., 2013a). 
Associations between negative symptoms and impaired aerobic fitness have been reported 
before in this population (Scheewe et al., 2013). However in contrast, Strassnig et al. (2011) 
found that aerobic fitness was only associated with the severity of positive symptoms and not 
with negative symptoms. More longitudinal and interventional research therefore is needed 
before firm conclusions related to any associations between psychiatric symptoms and aerobic 
fitness in patients with schizophrenia or schizoaffective disorder can be made. Unsurprisingly, 
the largest unique predictor of oxygen uptake was higher levels of physical activity 
participation, highlighting the importance of promoting activity in people with schizophrenia. 
The observation that antipsychotic medication use was not associated with a lower aerobic 
fitness is in accordance with previous research (Scheewe et al., 2013). The current data 
therefore indicates that the exposure to an unhealthy lifestyle rather than to antipsychotic 
medication use is associated with a worse performance on aerobic exercise tests. However, 
more longitudinal and interventional research is needed before any firm conclusions can be 
drawn. 
4.4. Feasibility 
The current study demonstrates that with an appropriately standardised method, the Astrand-
Rhyming test is highly reproducible in patients with schizophrenia or schizoaffective disorder 
facing motivation problems when performing physical activities (Vancampfort et al., 2013b). 
Only one test had to be terminated prematurely due to leg fatigue. Given present observations 
and its safety profile based on other studies in high-risk patients tested without complications 
(Lennon et al., 2012; Speelman et al., 2012; Thorsen et al., 2009), there appears to be no 
reason why physician attendance is required. In order to guarantee maximal safety, we 
recommend that the Astrand-Rhyming test is supervised by an experienced clinician (e.g., a 
mental health physical therapist) and should preferably be conducted in a setting which has 
medical cardiopulmonary resuscitation training expertise within a near proximity and on the 
same site location. The fact that no practice effects were observed has also important clinical 
implications since repeated tests are often cumbersome to implement in clinical trials and are 
less cost effective in clinic settings. 
 
4.5. Study limitations  
An important limitation of the present study is that it included only a sample of inpatients 
from one specific centre while it was pre-dominantly based on data obtained from male 
participants. This may affect the ability to generalise present results. However, the sample 
size was adequately powered and calculated a-priori. Despite these limitations, the present 
study clearly demonstrates that the Astrand-Rhyming sub-maximal exercise test is a reliable 
and feasible test to assess the aerobic fitness in patients with schizophrenia or schizoaffective 
disorder. Because it is easy to perform, safe and inexpensive, the test could be used in daily 
mental health care. Since we did not find any evidence for a practice effect, the elimination of 
a habituation trial will save time and reduce participant’s fatigue. The identification of a 
minimal detectable change of 6.5mlO2/min/kg supports the use of the Astrand-Rhyming sub-
maximal exercise test to identify patient-important change in research and clinical practice.  
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 Table 1 Medication use in assessed patients with schizophrenia or schizoaffective disorder (n = 47). 
 
No antipsychotic  3 (6.4%) 
Monotherapy antipsychotic   
          Amisulpride  3 (6.3%) 
          Aripiprazole  2 (4.2%) 
          Bromperidol  1 (2.1%) 
          Clotiapine  1 (2.1%) 
          Clozapine  4 (8.5%) 
          Quetiapine  2 (4.2%) 
          Olanzapine  8 (17.0%) 
          Paliperidone  9 (19.1%) 
Combination of  antipsychotics   
          Second‐generation  11 (23.4%) 
          First‐ and second generation  4 (8.5%) 
Other medication   
          Anticholinergic  3 (6.3%) 
          Antidepressant  15 (31.9%) 
          Benzodiazepine  10 (21.3%) 
          Mood stabiliser   7 (14.9%) 
          Somatic medication  12 (25.5%) 
 
Table 2 Physical co‐morbidity* in assessed patients with schizophrenia (n = 47). 
 
Respiratory tract diseases  4 (8.5%) 
Cardiovascular diseases  4 (8.5%) 
Thyroid diseases  1 (2.1%) 
Locomotor disorders  4 (8.5%) 
Viral diseases  1 (2.1%) 
Skin and connective tissue diseases  2 (4.2%) 
Metabolic Syndrome°   18 (38.3%) 
Diabetes  4 (8.5%) 
 
*Based on medical records; °According to International Diabetes Federation criteria (Alberti et al., 
2005).   
 
 
 
 
 
 
 
 
 
 
 
 Table 3 
Clinical  characteristics  for  the experimental group  (n = 47)  and Pearson Rho  correlations with  the 
estimated oxygen uptake on the second trial. 
 
        Mean±SD  Correlation with VO2   P 
 
Age (years)  34.2±11.2  ‐0.30  0.043* 
Illness duration (years)  12.5±11.6 ‐0.42 0.003*
BMI (kg/m2)  25.8±4.3  ‐0.53  <0.001* 
Chlorpromazine eq (mg/day)  649.6±410.3  ‐0.28  0.055 
Smoking (cigarettes/day)  13.1±11.8 ‐0.025 0.87
PECC positive symptoms  9.2±4.3  ‐0.20  0.18 
PECC negative symptoms  9.7±4.1  ‐0.41  0.004* 
PECC depressive symptoms  9.5±4.0  ‐0.41  0.005* 
PECC excitatory symptoms  8.2±3.7  0.047  0.75 
PECC cognitive symptoms  7.9±4.1 ‐0.48 0.001*
PECC extrapyramidal side‐effects  5.1±1.1  ‐0.40  0.006* 
IPAQ total (MET‐min/week)  785.7±508.5  0.69  <0.001* 
 
VO2=estimated  oxygen  uptake,  BMI=body  mass  index,  eq=equivalent,  PECC=Psychosis  Evaluation 
Tool  for  Common  Caregivers,  IPAQ=International  Physical  Activity  Questionnaire,  MET=metabolic 
equivalent; Significant when P<0.05.  
 
Table 4 
A backward regression model° with the estimated oxygen uptake as the dependent variable 
Model Unstandardised 
coefficients 
Standardised 
coefficients 
t P 
 B SE β   
(Constant) 42.1 4.3  9.7 <0.001* 
Illness duration (years) -0.24 0.07 -0.31 -3.2 0.002* 
PECC Negative 
symptoms  
-0.46 0.21 -0.22 -2.2 0.034* 
PECC Extrapyramidal 
side-effects 
-1.31 0.78 -0.17 -1.7 0.097 
IPAQ total (MET-
min/week) 
0.008 0.002 0.48 5.0 0.001* 
°All significant correlates were originally included in the model. The adjusted r² for the final 
model= 0.63. SE=standard error, PECC=Psychosis Evaluation Tool for Common Caregivers, 
IPAQ=International Physical Activity Questionnaire, MET=metabolic equivalent, *significant 
when P<0.05. 
 
 
Figure 1  
Flowchart of the eligible patients 
 
 
Excluded  (n = 11) 
Reasons: co-morbid substance 
abuse (n = 6), cardio-vascular or 
musculoskeletal problems (n = 3), 
use of beta-blocking agents (n = 2) 
Assessed for eligibility   
(n = 77) 
Included in the study 
(n = 66) 
Included in the final analyses 
(n = 47) 
Drop-out  
(n = 19) 
Reasons: not interested (n = 15), 
not motivated to participate in the 
second trial (n = 1), subjective 
somatic complaints prior to the test 
(n = 2); leg fatigue during the test 
(n = 1). 
6. Figure(s)
Figure 2  
Agreement assessment (Bland-Altman plot) of the Astrand-Rhyming test between time 1 (t1) 
and time 2 (t3) ( interval maximum 3 days) in patients with schizophrenia or schizoaffective 
disorder.  
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